Free Trial
NASDAQ:TVRD

Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Tvardi Therapeutics logo
$4.97 -0.19 (-3.68%)
As of 04:00 PM Eastern

About Tvardi Therapeutics Stock (NASDAQ:TVRD)

Advanced

Key Stats

Today's Range
$4.90
$5.16
50-Day Range
$5.16
$42.98
52-Week Range
$4.90
$43.65
Volume
259,684 shs
Average Volume
96,983 shs
Market Capitalization
$46.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.50
Consensus Rating
Hold

Company Overview

Tvardi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

TVRD MarketRank™: 

Tvardi Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 475th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tvardi Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Tvardi Therapeutics has a consensus price target of $55.50, representing about 1,014.5% upside from its current price of $4.98.

  • Amount of Analyst Coverage

    Tvardi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Tvardi Therapeutics' stock forecast and price target.
    • Percentage of Shares Shorted

      13.81% of the float of Tvardi Therapeutics has been sold short.
    • Short Interest Ratio / Days to Cover

      Tvardi Therapeutics has a short interest ratio ("days to cover") of 20.6, which indicates bearish sentiment.
    • Change versus previous month

      Short interest in Tvardi Therapeutics has recently increased by 26.02%, indicating that investor sentiment is decreasing significantly.
    • Dividend Yield

      Tvardi Therapeutics does not currently pay a dividend.

    • Dividend Growth

      Tvardi Therapeutics does not have a long track record of dividend growth.

    • Percentage of Shares Shorted

      13.81% of the float of Tvardi Therapeutics has been sold short.
    • Short Interest Ratio / Days to Cover

      Tvardi Therapeutics has a short interest ratio ("days to cover") of 20.6, which indicates bearish sentiment.
    • Change versus previous month

      Short interest in Tvardi Therapeutics has recently increased by 26.02%, indicating that investor sentiment is decreasing significantly.
    • News Sentiment

      Tvardi Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
    • News Coverage This Week

      MarketBeat has tracked 3 news articles for Tvardi Therapeutics this week, compared to 3 articles on an average week.
    • Search Interest

      15 people have searched for TVRD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
    • MarketBeat Follows

      4 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days.
    • Insider Buying vs. Insider Selling

      In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 3.10% of the stock of Tvardi Therapeutics is held by insiders.

    • Percentage Held by Institutions

      44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Tvardi Therapeutics' insider trading history.
    Receive TVRD Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    TVRD Stock News Headlines

    FY2025 EPS Estimates for TVRD Boosted by Cantor Fitzgerald
    NEW LAW: Congress Approves Setup For Digital Dollar?
    Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor Green, it's a bill that contains "the entire setup, groundwork and infrastructure to move from cash to digital currency."tc pixel
    See More Headlines

    TVRD Stock Analysis - Frequently Asked Questions

    Tvardi Therapeutics' stock was trading at $29.09 on January 1st, 2025. Since then, TVRD shares have decreased by 82.9% and is now trading at $4.98.

    Tvardi Therapeutics, Inc. (NASDAQ:TVRD) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.49. Tvardi Therapeutics had a negative net margin of 678.79% and a negative trailing twelve-month return on equity of 565.83%.

    Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Company Calendar

    Last Earnings
    8/14/2025
    Today
    10/24/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:TVRD
    Previous Symbol
    NASDAQ:TVRD
    CIK
    1346830
    Web
    N/A
    Employees
    80
    Year Founded
    2004

    Price Target and Rating

    High Price Target
    $78.00
    Low Price Target
    $15.00
    Potential Upside/Downside
    +1,014.5%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.29
    Research Coverage
    7 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$70.87 million
    Net Margins
    -678.79%
    Pretax Margin
    -453.48%
    Return on Equity
    -565.83%
    Return on Assets
    -66.71%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.04
    Quick Ratio
    4.04

    Sales & Book Value

    Annual Sales
    $7.14 million
    Price / Sales
    6.54
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($3.02) per share
    Price / Book
    -1.65

    Miscellaneous

    Outstanding Shares
    9,380,000
    Free Float
    9,086,000
    Market Cap
    $46.71 million
    Optionable
    N/A
    Beta
    0.24

    Social Links

     The Best Nuclear Energy Stocks to Buy Cover

    Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

    Get This Free Report

    This page (NASDAQ:TVRD) was last updated on 10/24/2025 by MarketBeat.com Staff
    From Our Partners